Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
General anaesthetic drugs are administered to patients for bringing state of reversible unconsciousness and unresponsiveness during and before time of surgery. They are administered by intravenous or by inhalational routes. In some cases, both intravenous and inhalation anaesthetic is used simultaneously as per the requirement. The patient loose consciousness and not feel any pain during and after the surgery if they are anaesthetized. They may feel short time memory loss (short amnesia). General anaesthetic drugs are chiefly used for bringing analgesia or pain relief, amnesia, reversible unconsciousness, motionless and inhibition of autonomic nervous system like increased blood pressure, heart rate and sweating and used for perform easy and safe surgery.
The general anaesthetic drug market is experiencing lucrative growth during the forecast period 2021-2027. The technological advancement in healthcare industries for safe and effective surgeries is gaining the market attention of general anaesthetic drug market. The dynamic factors like technological advancement in drug delivery devices is propelling the market growth of general anaesthetic drug market. The implementation of changes in anaesthesiology technique is also boosting the market growth. However, risk associated with general anaesthetic in paediatric patient and pregnant women is hindering the market growth of general anaesthetic drug market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the drug addiction treatment market. In addition, complete analysis of changes on drug addiction treatment expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. There is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027.
The general anaesthetic drug market is bifurcated by drug molecules, route of administration, end user and geography.
Drug molecules like isoflurane, desflurane, sevoflurane, ketamine, thiopental, opioids, propofol and other are comprised in general anaesthetic drug market. In which propofol is anticipated to dominate the market in 2020. The propofol is used in surgeries as well as sedative in critical care including COVID-19 patients. it is widely used for initiation and maintenance of procedural sedation, general anaesthesia. The propofol is short acting medication which results in decreased level of consciousness and lack of memory of situations. It is used as starting and maintenance of general anaesthesia, sedative for mechanically ventilated adults and procedural sedation.
Route of administrations like intravenous and inhalational are comprised in the general anaesthetic drug market. In which intravenous route is expected to dominate the market growth in 2020. The general anaesthetic drugs are less costly and not require any special equipment for administered is owing to propel the market growth. They also has less cardiac depression which is also refuelling the market growth of general anaesthetic drug market along with better postoperative analgesia is also elevating the market growth of general anaesthetic drug market.
End users like hospitals, speciality clinics and ambulatory surgical centres are comprised in the general anaesthetic drug market. In which hospitals is anticipated to dominate the market in 2020. The growth is attributed by high patient footfall in hospitals. Rising number of surgeries is also propelling the market growth. The adoption of technological advanced healthcare facilities is also propelling the market growth of segment. The rising population is also refuelling the market growth.
The general anaesthetic drug market is studied for the geographical areas like North America, Europe, Asia Pacific and rest of the world. In which North America is anticipate to witness tremendous growth during the forecast period 2021-2027. Increased adoption of novel therapeutics is propelling the market growth. New product launch is also refuelling the market growth. Increasing rate of surgeries is also refuelling the market growth. The increasing demand of advanced technologies and homecare facilities is also elevating market growth of general anaesthetic drug market.
The major key players in general anaesthetic drug market are Baxter International Inc. (Us), Hikma Pharmaceuticals Plc (Uk), Pfizer Inc. (Us), Piramal Enterprises Limited (India), Abbvie (Us), Fresenius Se & Co. Kgaa (Germany), Par Pharmaceutical (Us), Teva Pharmaceuticals (Israel), Viatris/Mylan (Us), Novartis Ag (Us), Abbott Laboratories (Us), Astrazeneca Plc (Us), F. Hoffmann-La Roche (Switzerland), Glaxosmithkline Plc (Uk), Gilead Sciences Inc. (Us), Bayer Ag (Germany), Merck & Co. Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (Us), Akorn (Us) and Apotex (Canada) among other are analysed.
August 2020: Fresenius Kabi launched their first medication with smart label embedded with radio-frequency identification technology. The first RFID smart labelled product, Diprivan (propofol) 200mg per 20mL (10mg per mL) injectables Emulsion, USP, was introduced in the US
July 2020: Acacia Pharma a group of PLC received U.S. FDA approval for BYFAVO (remimazolam) for injection for induction and maintenance of procedural sedation in adults undergoing procedures which lasts up to 30 minutes or less.
May 2020: Hikma Pharmaceutical PLC, a multinational pharmaceutical company, launched their propofol injectable emulsion, USP. 20ml, 50ml, 100ml vial in United States.
January 2020: Novartis AG acquired Aspen’s Japanese operations focused on generics and off-patent medicines.
The study comprised of general anaesthetic drug market. In which study analysed the various segments of the market. The general anaesthetic drug market is bifurcated by drug molecule, route of administration and end users. The study also comprised of dominating segment of the market. In the study it is profound that the drug molecule segment is dominated by propofol. Likewise, route of administration is dominated by intravenous route and end user segment is dominated by hospitals. The study also imparts the geographical section of the market and it concludes that North America is dominating the market in 2020. The study also comprised of impact on COVID-19 on the general anaesthetic drug market and it conclude that there is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027. The study also imparts the major key players operating in the regions.
Why to buy this report
